Sixfold Bioscience
Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company based in London, UK, focused on solving the critical challenge of RNA delivery. Using advanced AI, Bayesian Optimization, automated chemistry, and high throughput screening, they develop programmable drug delivery systems, particularly for short interfering RNA (siRNA) and messenger RNA (mRNA). Their innovative platform, Mergo®, is inspired by natural RNA delivery mechanisms and aims to unlock new cell types for treatment, expanding the potential of RNA therapeutics beyond traditional targets like the liver.
Industries
Nr. of Employees
small (1-50)
Sixfold Bioscience
Patents
Compositions containing nucleic acid nanoparticles with modular functionality
US-11357865-B2
View Details
Compositions containing nucleic acid nanoparticles with modular functionality
US-11357865-B2
View DetailsProducts
Mergo® platform
An AI-powered, evolution-inspired RNA delivery platform designed to target a wide range of tissues and cell types, beyond the liver.
RNA therapeutics (siRNA, mRNA)
Programmable RNA-based drugs for gene silencing and gene expression, with a focus on expanding therapeutic applications.
Mergo® platform
An AI-powered, evolution-inspired RNA delivery platform designed to target a wide range of tissues and cell types, beyond the liver.
RNA therapeutics (siRNA, mRNA)
Programmable RNA-based drugs for gene silencing and gene expression, with a focus on expanding therapeutic applications.
Services
RNA delivery platform development
Development of programmable drug delivery systems for RNA therapeutics, including siRNA and mRNA, using AI and automated chemistry.
Preclinical research and development
Conducting preclinical studies to evaluate the efficacy and safety of RNA delivery systems and therapeutics.
RNA delivery platform development
Development of programmable drug delivery systems for RNA therapeutics, including siRNA and mRNA, using AI and automated chemistry.
Preclinical research and development
Conducting preclinical studies to evaluate the efficacy and safety of RNA delivery systems and therapeutics.
News & Updates
Sixfold Bioscience will be a keynote speaker at the event in June 2025, discussing their RNA delivery innovations.
In July 2023, Sixfold's co-CEO participated in UK biotech policy discussions at Parliament.
In September 2019, the company received funding to advance its RNA delivery technology and analytical capabilities.
In July 2021, the company partnered with Pharmidex to accelerate preclinical development of oligonucleotide therapeutics.
An article discussing the potential of RNA and gene therapies in cancer treatment, highlighting Sixfold's role in delivery systems.
A feature on UK biotech initiatives, including Sixfold's contributions to RNA therapeutics.
Sixfold Bioscience will be a keynote speaker at the event in June 2025, discussing their RNA delivery innovations.
In July 2023, Sixfold's co-CEO participated in UK biotech policy discussions at Parliament.
In September 2019, the company received funding to advance its RNA delivery technology and analytical capabilities.
In July 2021, the company partnered with Pharmidex to accelerate preclinical development of oligonucleotide therapeutics.
An article discussing the potential of RNA and gene therapies in cancer treatment, highlighting Sixfold's role in delivery systems.
A feature on UK biotech initiatives, including Sixfold's contributions to RNA therapeutics.